MMP2 Role in Breast Cancer Brain Metastasis Development and Its Regulation by TIMP2 and ERK1/2

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2007 May 17

PMID 17505812

Citations 68

Authors

Odete Mendes

Hun-Taek Kim

Gina Lungu

George Stoica

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinase 2 (MMP2) is important in breast cancer (BC) invasion and metastasis. We previously reported that BC brain metastases, in a rat syngeneic model developed in our laboratory, have high expression and activity of MMP2. The MMP2 mechanism of action in the brain is still under intense scrutiny. To study the role of MMP2 in the development of BC brain metastasis we transfected ENU1564 rat mammary adenocarcinoma cells with tissue inhibitor of MMP2 (TIMP2). Animals inoculated with ENU1564-TIMP2 cells had decreased orthotopic tumor growth, decreased orthotopic metastatic behavior and did not develop brain metastases. These results were associated with decreased MMP2 activity, demonstrated by gel zymography. Mitogen activated protein kinase (MAPK) pathway components, such as ERK1/2, have been correlated to MMP expression and/or astrocyte activity. We found that BC brain metastases have peripheral astrocyte reactivity and higher expression of glial fibrillary acidic protein (GFAP) and phosphorylated-ERK1/2 (p-ERK1/2). Additionally, rat astrocyte-conditioned media increased in vitro invasion of ENU1564 cancer cells and increased expression of MMP2 and p-ERK1/2. Blockage of ERK1/2 phosphorylation by treatment with MEK inhibitor (PD98059) decreased the expression of MMP2 in cancer cells grown in rat astrocyte-conditioned media. Our results are highly suggestive that MMP2 plays a role in the development of BC metastases, in particular to the brain. Furthermore, our results suggest that astrocyte factors and the ERK1/2 signaling pathway may be associated with BC brain metastasis development; and that ERK1/2 may regulate MMP2 in a way that is modifiable by astrocyte factors.

Citing Articles

Identification of antimicrobial peptides from the Ambystoma mexicanum displaying antibacterial and antitumor activity.

Dastagir N, Liebsch C, Kutz J, Wronski S, Pich A, Obed D PLoS One. 2025; 20(3):e0316257.

PMID: 40043049 PMC: 11882074. DOI: 10.1371/journal.pone.0316257.

The research progress on meningeal metastasis in solid tumors.

Yue Y, Ren Y, Lu C, Jiang N, Wang S, Fu J Discov Oncol. 2025; 16(1):254.

PMID: 40019647 PMC: 11871263. DOI: 10.1007/s12672-025-01950-4.

Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.

Sutherland L, Lang J, Gonzalez-Juarbe N, Pickett B Curr Issues Mol Biol. 2024; 46(7):7114-7133.

PMID: 39057065 PMC: 11275280. DOI: 10.3390/cimb46070424.

Involvement of PAR-2 in the Induction of Cell-Specific Matrix Metalloproteinase-2 by Activated Protein C in Cutaneous Wound Healing.

Julovi S, McKelvey K, Minhas N, Chan Y, Xue M, Jackson C Int J Mol Sci. 2024; 25(1).

PMID: 38203540 PMC: 10779272. DOI: 10.3390/ijms25010370.

The origin of brain malignancies at the blood-brain barrier.

McDonald B, Barth K, Schmidt M Cell Mol Life Sci. 2023; 80(10):282.

PMID: 37688612 PMC: 10492883. DOI: 10.1007/s00018-023-04934-1.

References

Venugopal S, Devaraj S, Jialal I . Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol. 2005; 166(4):1265-71. PMC: 1602373. DOI: 10.1016/S0002-9440(10)62345-0. View

Kim M, Lee E, Kim H, Moon A . p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res. 2003; 63(17):5454-61. View

Levicar N, Nuttall R, Lah T, Nutall R . Proteases in brain tumour progression. Acta Neurochir (Wien). 2003; 145(9):825-38. DOI: 10.1007/s00701-003-0097-z. View

Nagashima G, Suzuki R, Fujimoto T . Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg. 2002; 104(2):125-31. DOI: 10.1016/s0303-8467(01)00197-4. View

Fromigue O, Louis K, Wu E, Belhacene N, Loubat A, Shipp M . Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase. Int J Cancer. 2003; 106(3):355-63. DOI: 10.1002/ijc.11232. View

Giraudon P, Szymocha R, Buart S, Bernard A, Cartier L, Belin M . T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-I-induced neurological disease. J Immunol. 2000; 164(5):2718-27. DOI: 10.4049/jimmunol.164.5.2718. View

Jaalinoja J, Herva R, Korpela M, Hoyhtya M, Turpeenniemi-Hujanen T . Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol. 2000; 46(1):81-90. DOI: 10.1023/a:1006421112839. View

Forough R, Lea H, Starcher B, Allaire E, Clowes M, Hasenstab D . Metalloproteinase blockade by local overexpression of TIMP-1 increases elastin accumulation in rat carotid artery intima. Arterioscler Thromb Vasc Biol. 1998; 18(5):803-7. DOI: 10.1161/01.atv.18.5.803. View

Saad S, Bendall L, James A, Gottlieb D, Bradstock K . Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Res Treat. 2000; 63(2):105-15. DOI: 10.1023/a:1006437530169. View

10.

Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, OHiggins N . High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer. 2001; 89(2):118-21. DOI: 10.1002/(sici)1097-0215(20000320)89:2<118::aid-ijc3>3.0.co;2-8. View

11.

Yoneda T . Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci. 2000; 5(1):75-81. DOI: 10.1007/s007760050012. View

12.

Leveque T, Le Pavec G, Boutet A, Tardieu M, Dormont D, Gras G . Differential regulation of gelatinase A and B and TIMP-1 and -2 by TNFalpha and HIV virions in astrocytes. Microbes Infect. 2004; 6(2):157-63. DOI: 10.1016/j.micinf.2003.11.006. View

13.

Christopherson K, Ullian E, Stokes C, Mullowney C, Hell J, Agah A . Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell. 2005; 120(3):421-33. DOI: 10.1016/j.cell.2004.12.020. View

14.

Zhao Y, Xiao A, Park H, Newcomer R, Yan M, Man Y . Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res. 2004; 64(2):590-8. DOI: 10.1158/0008-5472.can-03-1932. View

15.

Tester A, Waltham M, Oh S, Bae S, Bills M, Walker E . Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res. 2004; 64(2):652-8. DOI: 10.1158/0008-5472.can-0384-2. View

16.

Kazes I, Elalamy I, Sraer J, Hatmi M, Nguyen G . Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood. 2000; 96(9):3064-9. View

17.

Mendes O, Kim H, Stoica G . Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis. 2005; 22(3):237-46. DOI: 10.1007/s10585-005-8115-6. View

18.

Hanemaaijer R, Verheijen J, Maguire T, Visser H, Toet K, McDermott E . Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer. 2000; 86(2):204-7. DOI: 10.1002/(sici)1097-0215(20000415)86:2<204::aid-ijc9>3.0.co;2-6. View

19.

Liuzzi G, Mastroianni C, Latronico T, Mengoni F, Fasano A, Lichtner M . Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain. 2003; 127(Pt 2):398-407. DOI: 10.1093/brain/awh049. View

20.

Le D, Besson A, Fogg D, Choi K, Waisman D, Goodyer C . Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci. 2003; 23(10):4034-43. PMC: 6741112. View